-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompilationTom Lee
A few days ago, the U.
ALLO-715 is a CAR-T therapy targeting B cell maturation antigen (BCMA) and a potential new therapy for the treatment of multiple myeloma and other BCMA-positive malignancies
Phase 1 data from the UNIVERSAL trial proves that allogeneic CAR-T therapy for BCMA can achieve clinical response while eliminating the need for bridging therapy or manufacturing-related treatment delays
The test results also showed that CAR-T therapy ALLO-715 showed good tolerance in relapsed/refractory multiple myeloma.
Multiple myeloma is the second most common hematological malignancy after non-Hodgkin's lymphoma
In April 2021, ALLO-715 was again awarded the FDA Regenerative Medicine Advanced Therapy (RMAT) designation
Although the market space of CAR-T has great potential, the competition is also very fierce
Reference source:
1.
2.